Pressroom

Stay up to date with the latest news from DCL.  

PRESS RELEASE
Data Conversion Laboratory Partners with Generis to Deliver Content Reuse Solutions to the Life Sciences and Other Regulated Industries
Innovative Services Fueled by Artificial Intelligence, Machine Learning, and Natural Language Processing


Fresh Meadows, NY, February 3, 2021Data Conversion Laboratory (DCL), a leader in structured data and content transformations, and Generis, a leader of world-class, cloud-hosted content and regulatory information management solutions, today announce a strategic global partnership that enables life sciences and other regulated industries to accelerate structured content authoring (SCA) and structured content management (SCM) initiatives for both current and legacy documents.


Information accuracy, traceability, and compliance are critical in life sciences, along with speed to market. DCL helps businesses organize and structure data and content for use and reuse in new ways across modern technologies and platforms.  A long-time industry leader in Structured Product Labelling (SPL) conversion services for global pharma companies, DCL now empowers organizations to go beyond merely meeting government guidelines. By improving content structure and data management  throughout the drug development life cycle, organizations achieve workflow efficiencies while also improving patient outcomes.


This partnership enables clients to reduce dependencies on legacy systems and transform the way they interact with content. Leveraging Generis’s flagship CARA™ Life Sciences Platform, organizations can streamline business processes by combining structured content and component-based authoring, review, approval, and publishing with audit trails on a single, user-friendly platform.


“This collaboration represents a great meeting of minds,” states Mark Gross, President at DCL. “Generis’s innovative structured content authoring technology solves complex content and information management problems faced by life sciences as well as other regulated enterprises. By combining our respective solutions, the partnership allows clients to adopt an end-to-end structured content authoring process that bridges the gap between departments to create a continuous workflow and a better user journey.”


DCL’s ability to reliably convert legacy information into useable formats enables comprehensive use of structured content authoring with Generis’s CARA platform. True digital transformation empowers organizations to maximize content interchange, streamline workflows, and process information efficiently and accurately. DCL also provides strategic guidance and tools to clients as they evaluate existing content, to rapidly identify the potential value from content reuse and where to focus conversion efforts.


“Transforming legacy content into useable formats for structured content authoring benefits clients working in a range of sectors including life sciences,” explains James Kelleher, Founder and CEO at Generis. “DCL is fluent across all content types and industry standards and we are thrilled to partner with such a progressive organization.”


About Data Conversion Laboratory
Data Conversion Laboratory (DCL) provides data and content transformation services and solutions. Using the latest innovations in artificial intelligence, including machine learning and natural language processing, DCL helps businesses organize and structure data and content for modern technologies and platforms. With expertise across many industries including publishing, life sciences, government, manufacturing, technology and professional organizations, DCL uses its advanced technology and U.S.-based project management teams to solve the most complex conversion challenges securely, accurately and on time. DCL is the industry leader in XML content conversion, DITA conversion, S1000D conversion, SPL conversion services, and so much more. Founded in 1981, DCL was named one of EContent's Top 100 Companies in the Digital Content Industry.


About Generis

Generis is a UK-headquartered developer of world-class Content and Regulatory Information Management technology for regulated industries globally. Eight of the top 10 global life sciences companies rely on Generis’s flagship Intelligent Content Services platform, CARA™, for critical document and information management, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer and Merck KGaA. Today Generis serves more than half a million users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. Find out more at: https://www.generiscorp.com